Related Experiment Video
Updated: Jun 25, 2026

09:30
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
Laboratory Perspectives on Assay Selection and Implementation of PlGF-Based Testing for Suspected Preterm
Paul M Yip1, Lei Fu1
1Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON.
Summary
Placental Growth Factor (PlGF) testing for preeclampsia is becoming common in Canada. However, standardized guidance on diagnostic thresholds and assay selection is needed for effective clinical implementation.
Area of Science:
- Obstetrics and Gynecology
- Clinical Chemistry
- Biomarker Discovery
Background:
- Blood-based biomarker testing for Placental Growth Factor (PlGF) for preeclampsia is increasingly adopted in Canada.
- Diagnostic assays for PlGF are becoming more accessible.
- Current guidance on diagnostic and prognostic thresholds for PlGF tests is not standardized.
Purpose of the Study:
- To review currently available PlGF assays in Canada.
- To discuss studies on preterm preeclampsia using PlGF.
- To address technical considerations for PlGF assay implementation.
Main Methods:
- Literature review of PlGF assays and their associated studies.
- Analysis of single cut-offs versus gestational age ranges for PlGF testing.
- Examination of technical aspects including assay configuration, handling, and interpretation.
Main Results:
- Multiple PlGF assays are available in Canada, but their thresholds are not interchangeable.
- Studies show varying performance of PlGF tests in preterm preeclampsia.
- Laboratory support is crucial for selecting and interpreting PlGF assays.
Conclusions:
- Standardized guidance is needed for PlGF testing in preeclampsia.
- Clinicians and laboratory stakeholders require support for assay selection and interpretation.
- Further research is necessary to establish universal thresholds and best practices for PlGF testing.

